Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Adaptive Randomized Neoadjuvant Two Arm Trial in Triple-negative Breast Cancer Comparing a Mono Atezolizumab Window Followed by a Atezolizumab - CTX Therapy With Atezolizumab - CTX Therapy (neoMono)

NCT04770272 is registered in ClinicalTrials.gov with Palleos Healthcare GmbH as lead sponsor.

NCT NCT04770272
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04770272 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Adaptive Randomized Neoadjuvant Two Arm Trial in Triple-negative Breast Cancer Comparing a Mono Atezolizumab Window Followed by a Atezolizumab - CTX Therapy With Atezolizumab - CTX Therapy (neoMono)
Lead sponsor
Palleos Healthcare GmbH
Phase
Phase 2
Overall status
Terminated
Start date
March 1, 2021
Completion date
October 2, 2024
Enrollment
442 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

triple-negative breast cancer